Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia

Bruno Quintino de Oliveira; Luiz F B Catto; Bárbara A A Santana; M Florencia Tellechea; Priscila S Scheucher; Phillip Scheinberg; Rodrigo T Calado

doi:10.1111/bjh.17140

Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia

Br J Haematol. 2021 Apr;193(2):410-414. doi: 10.1111/bjh.17140. Epub 2020 Nov 20.

Authors

Bruno Quintino de Oliveira¹, Luiz F B Catto¹, Bárbara A A Santana¹, M Florencia Tellechea¹, Priscila S Scheucher¹, Phillip Scheinberg², Rodrigo T Calado¹

Affiliations

¹ Department of Medical Imaging, Haematology, and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil.
² Division of Haematology, Hospital A Beneficência Portuguesa, São Paulo, SP, Brazil.

PMID: 33216370
DOI: 10.1111/bjh.17140

Abstract

Eltrombopag has been added to first-line treatment of immune aplastic anaemia (AA), resulting in higher responses. We analysed marrow samples of AA patients who responded to immunosuppressive therapy (IST) alone or in combination with eltrombopag for the composition of the haematopoietic stem and progenitor cell (HSPC) compartment. The number of CD34⁺ cells and multipotent progenitors was higher in patients treated with eltrombopag (P < 0·005; P < 0·05; respectively), but not the number of stem cells. No aberrant phenotype was observed. These results indicate that eltrombopag augments CD34⁺ cells in vivo and preferentially expands multipotent progenitors, but not stem cells.

Keywords: aplastic anaemia; eltrombopag; flow cytometry; haematopoietic stem cells; thrombopoietin receptor agonist.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Anemia, Aplastic / drug therapy*
Antigens, CD34 / drug effects
Benzoates / administration & dosage
Benzoates / pharmacology*
Biopsy, Needle / methods
Bone Marrow Cells / cytology
Bone Marrow Cells / drug effects
Bone Marrow Cells / pathology
Brazil / epidemiology
Female
Flow Cytometry / methods
Hematopoietic Stem Cells / cytology
Hematopoietic Stem Cells / drug effects*
Humans
Hydrazines / administration & dosage
Hydrazines / pharmacology*
Immunosuppressive Agents / therapeutic use
Male
Middle Aged
Multipotent Stem Cells / cytology
Multipotent Stem Cells / drug effects*
Pyrazoles / administration & dosage
Pyrazoles / pharmacology*
Receptors, Thrombopoietin / agonists*

Substances

Antigens, CD34
Benzoates
Hydrazines
Immunosuppressive Agents
Pyrazoles
Receptors, Thrombopoietin
MPL protein, human
eltrombopag